InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Announcements

- Current share price for NUZ : $0.060

ASX company news and announcements for Neurizon Therapeutics Limited (NUZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurizon Therapeutics Limited (NUZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurizon Therapeutics Limited (NUZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurizon Therapeutics Limited (NUZ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$47 Neurizon Completes GMP Tablet Registration Batches 4 Dec 2025 8:54AM $0.105 $0.060 fallen by 42.86%
$47 Amended Constitution 3 Dec 2025 2:35PM $0.105 $0.060 fallen by 42.86%
$47 Results of Annual General Meeting 26 Nov 2025 7:05PM $0.105 $0.060 fallen by 42.86%
$47 AGM Presentation 26 Nov 2025 2:51PM $0.105 $0.060 fallen by 42.86%
$47 Chairman's AGM Address 26 Nov 2025 2:49PM $0.105 $0.060 fallen by 42.86%
$47 Elanco executive appointed as Board Observer 26 Nov 2025 9:16AM $0.110 $0.060 fallen by 45.45%
$47 Section 708A Cleansing Statement 31 Oct 2025 3:27PM $0.118 $0.060 fallen by 48.94%
$47 Application for quotation of securities - NUZ 31 Oct 2025 3:17PM $0.118 $0.060 fallen by 48.94%
$47 Neurizon to present Q1 FY2026 Results 31 Oct 2025 9:35AM $0.110 $0.060 fallen by 45.45%
$47 Appendix 4C & Quarterly Update 29 Oct 2025 9:42AM $0.125 $0.060 fallen by 52%
$47 Notice of Annual General Meeting/Proxy Form 23 Oct 2025 9:15AM $0.130 $0.060 fallen by 53.85%
$47 Australian Patent Granted for NUZ-001 21 Oct 2025 9:09AM $0.135 $0.060 fallen by 55.56%
$47 Quarterly Shareholder Update Webinar - Q1 FY2026 20 Oct 2025 4:17PM $0.135 $0.060 fallen by 55.56%
$47 Neurizon to Present Poster Data at 2025 NEALS Annual Meeting 10 Oct 2025 8:41AM $0.140 $0.060 fallen by 57.14%
$47 Proposed issue of securities - NUZ 8 Oct 2025 9:35AM $0.140 $0.060 fallen by 57.14%
$47 Neurizon Commences Trading on OTCQB Venture Market 8 Oct 2025 9:30AM $0.140 $0.060 fallen by 57.14%
$47 FDA Lifts Clinical Hold on NUZ-001 6 Oct 2025 8:55AM $0.145 $0.060 fallen by 58.62%
$47 Notification regarding unquoted securities - NUZ 1 Oct 2025 5:44PM $0.125 $0.060 fallen by 52%
$47 Section 708A Cleansing Statement 24 Sep 2025 9:32AM $0.145 $0.060 fallen by 58.62%
$47 Application for quotation of securities - NUZ 23 Sep 2025 11:24AM $0.145 $0.060 fallen by 58.62%
$47 R&D Tax Incentive Advance & Overseas Finding Approval 18 Sep 2025 9:25AM $0.140 $0.060 fallen by 57.14%
$47 Proposed issue of securities - NUZ 18 Sep 2025 9:25AM $0.140 $0.060 fallen by 57.14%
$47 Neurizon Raises $5m via Institutional Placement 18 Sep 2025 9:25AM $0.140 $0.060 fallen by 57.14%
$47 Trading Halt 16 Sep 2025 9:29AM $0.140 $0.060 fallen by 57.14%
$47 Change of AGM Date 1 Sep 2025 6:32PM $0.155 $0.060 fallen by 61.29%

76 - 100 of 169 results

Page 4 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.